TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Orexo AB ( (SE:ORX) ) just unveiled an update.
Orexo AB reported a decrease in net revenues and a negative EBITDA for Q3 2025, with significant costs associated with LTIP programs impacting financial results. However, the company showcased positive in-vivo data for a new intranasal GLP-1 agonist medication supported by its AmorphOX® technology and secured a substantial award from BARDA for developing an intranasal rescue medication, indicating potential future growth and innovation.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo AB is a commercial-stage pharmaceutical company that develops drugs using cutting-edge drug delivery technologies. The company is committed to the UN Global Compact corporate responsibility initiative, focusing on human rights, labor, environment, and anti-corruption.
Average Trading Volume: 68,221
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.32B
See more data about ORX stock on TipRanks’ Stock Analysis page.